These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 21059168)

  • 1. The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review.
    Pedersen RH; Lohse N; Østergaard L; Søgaard OS
    HIV Med; 2011 Jul; 12(6):323-33. PubMed ID: 21059168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.
    Rossheim AE; Young AM; Siik J; Cunningham TD; Troy SB
    Hum Vaccin Immunother; 2016 Aug; 12(8):2117-2123. PubMed ID: 27172241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal Vaccination Strategies Among HIV-infected Adult Patients: A Review of the Literature.
    Garmpi A; Damaskos C; Garmpis N; Patsouras A; Savvanis S; Gravvanis N; Diamantis E
    In Vivo; 2019; 33(5):1425-1430. PubMed ID: 31471388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
    Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
    Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults.
    Peñaranda M; Payeras A; Cambra A; Mila J; Riera M;
    AIDS; 2010 May; 24(8):1226-8. PubMed ID: 20299956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in pneumococcal vaccines: what are the advantages for the elderly?
    Vila-Córcoles A
    Drugs Aging; 2007; 24(10):791-800. PubMed ID: 17896829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination among HIV-infected, HIV-exposed uninfected and HIV-uninfected children: a systematic review and meta-analysis of evidence related to vaccine efficacy and effectiveness.
    Adetokunboh OO; Ndwandwe D; Awotiwon A; Uthman OA; Wiysonge CS
    Hum Vaccin Immunother; 2019; 15(11):2578-2589. PubMed ID: 30945967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
    Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
    Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.
    French N; Nakiyingi J; Carpenter LM; Lugada E; Watera C; Moi K; Moore M; Antvelink D; Mulder D; Janoff EN; Whitworth J; Gilks CF
    Lancet; 2000 Jun; 355(9221):2106-11. PubMed ID: 10902624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults.
    Ohtola JA; Khaskhely NM; Saul-Mcbeth JL; Iyer AS; Leggat DJ; Khuder SA; Westerink MAJ
    Vaccine; 2016 Jan; 34(4):451-457. PubMed ID: 26707220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
    Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
    J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials.
    Diao WQ; Shen N; Yu PX; Liu BB; He B
    Vaccine; 2016 Mar; 34(13):1496-1503. PubMed ID: 26899376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
    Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
    AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.
    French N; Moore M; Haikala R; Kayhty H; Gilks CF
    J Infect Dis; 2004 Aug; 190(4):707-12. PubMed ID: 15272398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.
    Teshale EH; Hanson D; Flannery B; Phares C; Wolfe M; Schuchat A; Sullivan P
    Vaccine; 2008 Oct; 26(46):5830-4. PubMed ID: 18786586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal nasopharyngeal carriage among infants born to human immunodeficiency virus-infected mothers immunized with pneumococcal polysaccharide vaccine during gestation.
    Almeida Vde C; Negrini BV; Cervi MC; Isaac Mde L; Mussi-Pinhata MM
    Pediatr Infect Dis J; 2011 Jun; 30(6):466-70. PubMed ID: 21200361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children.
    Jallow S; Madhi SA
    Expert Rev Vaccines; 2017 May; 16(5):453-465. PubMed ID: 28351187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.